Abbreviations {#nomen0010}
=============

BCSS

:   Breast cancer cause-specific survival

CS-TNBC

:   carcinosarcoma-TNBC

CS-non TNBC

:   carcinosarcoma-non TNBC

IDC

:   Invasive ductal carcinoma

OS

:   Overall survival

PSM

:   Propensity score matching

SEER

:   Surveillance, Epidemiology, and End Results

TNBC

:   Triple negative breast cancer

TNM

:   Tumor Node Metastasis

1. Introduction {#sec1}
===============

Breast carcinosarcoma is a rare histological cancer that occurs in 0.08%--0.2% of all cases of breast cancer \[[@bib1]\]. It was first reported by Halpert B and Young MO in 1948 \[[@bib2]\]. In the World Health Organization (WHO) breast cancer classification (2003), breast carcinosarcoma was characterized as infiltrating carcinoma mixed with heterologous malignant mesenchymal component and was defined as a subtype of metaplastic carcinoma. The term "metaplastic carcinoma" refers to a heterogeneous group of neoplasms characterized by an intimate admixture of adenocarcinoma with dominant areas of spindle cell, squamous, and/or mesenchymal differentiation \[[@bib3]\]. In 2012, WHO published a revised classification for metaplastic carcinoma. In this edition, "breast carcinosarcoma" is replaced by "metaplastic breast cancer with mesenchymal differentiation", and other subtypes of metaplastic breast cancer are squamous cell carcinoma, low-grade adenosquamous carcinoma, spindle cell carcinoma, and fibromatosis-like metaplastic carcinoma \[[@bib4]\]. Compared with invasive ductal carcinoma (IDC), the most common type of breast cancer, patients diagnosed with metaplastic carcinoma are more likely to have larger tumor size, less lymph node metastasis, a higher histology grade and percent of triple negative breast cancer (TNBC), and a worse clinical outcome \[[@bib5], [@bib6], [@bib7]\].

Due to the specific histologic feature, breast carcinosarcoma may have different biological characteristics when compared with IDC. Because of the rarity of breast carcinosarcoma, previous publications about this disease were a few small sample size retrospective analyses \[[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]\] and a few case reports \[[@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\]. From these limited studies, it appears that breast carcinosarcoma is always aggressive, poorly differentiated, and hormone receptor-negative \[[@bib8],[@bib10]\]. Some reports showed that patients with carcinosarcoma had worse survival than other subtypes of metaplastic carcinomas \[[@bib8],[@bib11]\]; however, one report showed that carcinosarcoma shared a similar clinical outcome with other metaplastic carcinomas \[[@bib10]\]. Until now, accurate information concerning the comparison of breast carcinosarcoma and breast IDC has been unavailable.

The aim of the study was to perform a comparison of the prognosis between breast carcinosarcoma and breast IDC, and to further identify the underlying prognostic clinicopathological factors.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

The Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2015 was used to collect patients' clinicopathological features and survival data. This database includes authoritative information about cancer incidence and survival data from 18 population-based cancer registries, covering approximately 34.6% of the U.S. population \[[@bib21]\]. Since the HER2 information was available after 2010, we collected the SEER patients diagnosed between 2010 and 2015. Other selection criteria were as follows: breast cancer as the only cancer diagnosis, Tumor Node Metastasis (TNM) stage I--IV and pathologic confirmation of carcinosarcoma (ICD-0-3 8980/3, and 8981/3) and infiltrating duct carcinoma, not otherwise specified (ICD-0-3 8500).

2.2. Clinicopathological characteristics {#sec2.2}
----------------------------------------

To investigate the clinicopathological characteristics of carcinosarcoma and infiltrating duct carcinoma of the breast, the following information was obtained: age, race, marital status at diagnosis, laterality, grade, TNM stage, tumor size, nodal stage, metastasis status, breast molecular subtype, surgery treatment with either mastectomy or breast-conserving surgery, radiation therapy, chemotherapy, cause of death, and survival (months). Patients were categorized into four subtypes: HR + HER2-, HR + HER2+, HR-HER2+, HR-HER2- (triple negative).

2.3. Statistical analyses {#sec2.3}
-------------------------

Breast cancer cause-specific survival (BCSS) was defined as the time from the date of diagnosis to the date of death from breast cancer. Overall survival (OS) was defined as the time from the date of diagnosis to the date of death due to any cause or the last follow-up. Clinicopathological characteristics were compared between carcinosarcoma and infiltrating duct carcinoma by Pearson chi-square and Fisher's exact probability tests. The univariate Cox proportional hazard model was applied for identifying prognostic factors. Kaplan-Meier plots and log-rank tests were performed to compare BCSS and OS among different groups. Propensity score matching was conducted to calibrate the effects of the baseline of clinicopathological differences. All the statistical analyses and graphics were performed with the SPSS statistical software, version 22.0 (IBM Corp, Armonk, NY) and R statistical software (version 3.6.0. <http://www.R-proje> ct.org/).

3. Results {#sec3}
==========

3.1. Patient, clinical, and tumor characteristics {#sec3.1}
-------------------------------------------------

Between the years 2010 and 2015, a total of 63 patients with breast carcinosarcoma and 200,596 with breast IDC were identified in our study. The detailed clinicopathological characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. There were significant differences between carcinosarcoma and IDC, including Grade, AJCC stage, T stage, N stage, molecular subtype, and treatment options. Compared with IDC, patients with carcinosarcoma had higher grade (III--IV, 87.3% vs. 36.8%, P = 0.000), higher stage (II--IV, 88.9% vs. 49.3%, P = 0.000), larger tumor size (\>2 cm, 84.2% vs. 40%, P = 0.000), lower lymph node involvement (negative, 77.8% vs. 66.3%, P = 0.040), and higher proportion of TNBC (68.3% vs.12.3%, P = 0.000). There was no significant difference in the rate of distant metastasis (M1, 7.9% vs. 5.0%, P = 0.247). Concerning treatment options, patients with carcinosarcoma were more likely to receive mastectomy (73.0% vs. 35.6%, P = 0.000) and chemotherapy (73.0% vs. 44.2%, P = 0.000), while less likely to receive radiotherapy (30.2% vs. 52.1%, P = 0.001).Table 1Baseline characteristics of patients with carcinosarcoma and invasive ductal carcinoma (IDC).Table 1CharacteristicsCarcinosarcoma (n = 63) NoPercent (%)IDC (n = 200,596) NoPercent (%)PAge0.314 ＜60 years3657.1100,93750.3 ≥60 years2742.999,66649.7Race0.208 Black1320.623,46711.7 White4469.8155,33577.4 Other69.520,26810.1 Unknown0015330.8Grade0.000 I0039,13119.5 II11.680,14740.0 III5181.073,32036.5 IV46.36160.3 Unknown711.173893.7Laterality0.904 Left3149.2101,72650.7 Right3250.898,72849.2 Others001490.1Marital status0.087 Married2946.0111,10355.4 Unmarried3352.479,15239.5 Unknown11.610,3485.16Stage0.000 I711.1101,72650.7 II3961.967,11533.5 III1219.021,72210.8 IV57.910,0405.0T stage0.000 T0001720.1 T1914.3118,92159.3 T22539.761,00230.4 T31930.210,8485.4 T4914.384434.2 Unknown11.612170.6N stage0.040 N04977.8133,01266.3 N1711.149,60324.7 N246.310,8045.4 N323.262783.1 Unknown11.69060.5Metastasis0.247 M05892.1190,56395.0 M157.910,0405.0Molecular subtype0.000 HR + HER2-1320.6130,04464.8 HR-HER2+23.210,6705.3 HR + HER2-23.223,57111.8 Triple negative4368.324,62812.3 Unknown34.811,6905.8Surgery0.000 No surgery46.314,9617.5 breast-conserving surgery1320.6113,77656.7 Mastectomy4673.071,42435.6 Unknown004420.2Radiation0.001 Yes1930.2104,45852.1 No/unknown4469.896,14547.9Chemotherapy0.000 Yes4673.088,60044.2 No/unknown1727.0112,00355.8

3.2. Comparison of survival between breast carcinosarcoma and breast IDC {#sec3.2}
------------------------------------------------------------------------

Based on the Kaplan--Meier plot, carcinosarcoma showed a significantly worse clinical outcome than breast IDC ([Fig. 1](#fig1){ref-type="fig"}, both P \< 0.0001). The 4-year BCSS rate in carcinosarcoma and IDC was 49.6% and 91.3%, respectively, and the 4-year OS rate in carcinosarcoma and IDC was 46.2%, and 87.4%, respectively. Since TNBC was a poor prognostic molecular subtype for breast cancer, and 68.3% of carcinosarcomas were TNBC, we further compared BCSS and OS among the following subgroups: IDC- TNBC, IDC-non TNBC, carcinosarcoma-TNBC (CS-TNBC), and carcinosarcoma-non TNBC (CS-non TNBC). The results are presented in [Fig. 2](#fig2){ref-type="fig"}. Patients with CS-TNBC and CS-non TNBC have similar BCSS and OS (both P \> 0.05). These two groups displayed worse clinical outcomes than those with IDC- TNBC and IDC-non TNBC (both P \< 0.05).Fig. 1Kaplan--Meier curves showing a comparison of cancer cause-specific survival (a) and overall survival (b) between invasive ductal carcinoma (IDC) and carcinosarcoma (CS).Fig. 1Fig. 2Kaplan--Meier curves showing a comparison of breast cancer cause-specific survival (a) and overall survival (b) among invasive ductal carcinoma--non TNBC (IDC-non TNBC), IDC-TNBC, carcinosarcoma-non TNBC (CS-non TNBC), and carcinosarcoma-TNBC (CS-TNBC).Fig. 2

Since the uneven baseline characteristics may have a marked impact on the survival outcomes, we performed a 1:5 (carcinosarcoma/IDC) propensity score matching analysis to the utmost to eliminate the baseline variations. Eleven patients with carcinosarcoma were excluded due to lack of definite baseline characteristics. Finally, 260 IDC patients were selected to match 52 carcinosarcomas. No significant differences were observed for all of the baseline variations between the matched groups ([Table 2](#tbl2){ref-type="table"}). The patients with carcinosarcoma exhibited a poorer clinical outcome than IDC patients. The 4-year BCSS rate in carcinosarcoma and IDC was 50.1%, and 76.9%, respectively (P = 0.0018, log-rank test), and the 4-year OS rate in carcinosarcoma and IDC was 47.0% and 69.3%, respectively (P = 0.0048, log-rank test) ([Fig. 3](#fig3){ref-type="fig"}).Table 2Baseline characteristics of patients with carcinosarcoma and invasive ductal carcinoma (IDC) in 1:5 matched group.Table 2CharacteristicsCarcinosarcoma (n = 52) NoPercent (%)IDC (n = 260) NoPercent (%)PAge0.718 ＜60 years3261.515358.8 ≥60 years2038.510741.2Race0.689 Black1223.15521.2 White3669.219073.1 Other47.7155.8Grade0.928 II11.993.5 III4892.323188.8 IV35.8207.7Laterality0.541 Left2548.111142.7 Right2751.914957.3Marital status0.880 Married265013451.5 Unmarried265012648.5Stage0.676 I611.53212.3 II3363.516262.3 III917.35521.2 IV47.7114.2T stage0.400 T1815.44015.4 T22140.411443.8 T31732.75922.7 T4611.54718.1N stage0.184 N04076.919575.0 N1713.55220.0 N235.8114.2 N323.820.8Metastasis0.288 M04892.324995.8 M147.7114.2Molecular subtype0.920 HR + HER2-1121.25521.2 HR-HER2+23.8197.3 HR + HER2+23.8124.6 Triple negative3771.217466.9Surgery1.000 No surgery11.993.5 breast-conserving surgery1121.25420.8 Mastectomy4076.919775.8Radiation0.748 Yes1630.88934.2 No/unknown3669.217165.8Chemotherapy1.000 Yes397519474.6 No/unknown13256625.4Fig. 3The comparison of survival in the 1:5 matching group conducted between carcinosarcoma (CS) and invasive ductal carcinoma (IDC). (a) breast cancer cause-specific survival (BCSS); (b) overall survival (OS).Fig. 3

Then we used the same strategy to match CS-TNBC. Finally, we obtained 37 patients with CS-TNBC and 185 matched patients with IDC-TNBC. No significant differences were observed for all of the baseline variations between the two groups ([Table 3](#tbl3){ref-type="table"}). We observed an inferior outcome for CS-TNBC compared with IDC-TNBC. The 4-year BCSS rate in CS-TNBC and IDC-TNBC was 58.9% and 81.7%, respectively (P = 0.0032, log-rank test), and the 4-year OS rate in CS-TNBC and IDC-TNBC was 53.9% and 75.2%, respectively (P = 0.0071, log-rank test) ([Fig. 4](#fig4){ref-type="fig"}).Table 3Baseline characteristics of patients with carcinosarcoma-TNBC (CS-TNBC) and invasive ductal carcinoma-TNBC (IDC-TNBC) subgroup in 1:5 matched group.Table 3CharacteristicsCS-TNBC (n = 37) NoPercent (%)IDC-TNBC (n = 185) NoPercent (%)PAge1.000 ＜60 years2156.810858.4 ≥60 years1643.27741.6Race0.704 Black616.22614.1 White2875.713472.4 Other38.12513.5Grade1.000 I0010.5 II12.763.2 III3389.216488.6 IV38.1147.6Laterality0.856 Left1745.97942.7 Right2054.110657.3Marital status1.000 Married2054.19853.0 Unmarried1745.98747.0Stage0.820 I410.82010.8 II2567.612064.9 III616.23921.1 IV25.463.2T stage0.583 T1513.52211.9 T21437.87339.5 T31540.56032.4 T438.13016.2N stage0.808 N03183.814477.8 N138.12714.6 N225.484.3 N312.763.2Metastasis0.623 M03594.617996.8 M125.463.2Surgery1.000 No surgery12.773.8 breast-conserving surgery924.34423.8 Mastectomy2773.013472.4Radiation1.000 Yes1437.87138.4 No/unknown2362.211461.6Chemotherapy1.000 Yes2978.414880 No/unknown821.63720Fig. 4The comparison of survival in the 1:5 matching group conducted between carcinosarcoma-TNBC (CS-TNBC) and invasive ductal carcinoma-TNBC (IDC-TNBC). (a) breast cancer cause-specific survival (BCSS); (b) overall survival (OS).Fig. 4

3.3. Identifying prognostic factors for carcinosarcoma {#sec3.3}
------------------------------------------------------

We also explored the potential prognosis factor in breast carcinosarcoma using univariate Cox regression analysis. As shown in [Table 4](#tbl4){ref-type="table"}, stage, tumor size, and distant metastasis were all significantly associated with poor BCSS and OS. Other factors such as grade (P = 0.028, grade III, HR = 0.246, 95% CI, 0.070--0.859), N stage (P = 0.003, unknown, HR = 73.170, 95% CI, 4.503--1189.004), and molecular subtype (P = 0.009, unknown, HR = 10.759, 95% CI, 1.806--64.103) were also prognostic factors for OS.Table 4Prognostic factors for breast cancer caused-specific survival (BCSS) and overall survival (OS) in breast carcinosarcoma by univariate analyses.Table 4ParameterBCSSOSHR (95% CI)PHR (95% CI)PAge ＜60 years11 ≥60 years2.263 (0.935--5.474)0.0701.999 (0.880--4.542)0.098Race Black11 White1.407 (0.466--4.249)0.5451.593 (0.535--4.744)0.403 Other1.285 (0.140--11.753)0.8242.419 (0.432--13.548)0.315Laterality Left11 Right0.718 (0.296--1.745)0.4650.969 (0.425--2.208)0.941Marital status Married11 Unmarried2.362 (0.856--6.514)0.0972.227 (0.876--5.661)0.093 Unknown00.98600.985Grade IV11 II00.98200.984 III0.310 (0.069--1.387)0.1250.246 (0.070--0.859)0.028 Unknown0.449 (0.073--2.774)0.3890.314 (0.062--1.601)0.163Stage I-II11 III-IV3.041 (1.230--7.515)0.0163.973 (1.714--9.209)0.001T stage T1-T211 T3-T43.392 (1.262--9.115)0.0154.091 (1.571--10.652)0.004 Unknown63.01 (5.130--773.970)0.00148.659 (4.502--525.919)0.001N stage N011 N1--N31.329 (0.477--3.706)0.5861.859 (0.748--4.623)0.182 Unknown00.99073.170 (4.503--1189.004)0.003Metastasis M011 M110.733 (3.017--38.180)0.0007.647 (2.284--25.603)0.001Molecular subtype Non-triple negative11 Triple negative0.858 (0.325--2.261)0.7560.986 (0.382--2.545)0.977 Unknown6.516 (0.652--65.132)0.11110.759 (1.806--64.103)0.009Surgery No surgery11 breast-conserving surgery1 (0.004--281.607)1.0001 (0.010--103.820)1.000 Mastectomy1 (0.004--269.101)1.0001 (0.010--98.900)1.000Radiation Yes11 No/unknown1.283 (0.491--3.349)0.6111.240 (0.509--3.024)0.636Chemotherapy Yes11 No/unknown1.998 (0.795--5.020)0.1411.954 (0.826--4.620)0.127

4. Discussion {#sec4}
=============

Breast carcinosarcoma is a rare disease. Only 358 patients were registered in the SEER database between the years 1973 and 2015. Because Her-2 is an important molecular subtype factor and this information is only available after 2010, we collected the SEER patients diagnosed between 2010 and 2015. Finally, only 63 patients with breast carcinosarcoma were identified in the present study.

Our study showed that the 4-year BCSS rate and OS rate of carcinosarcoma was 49.6% and 46.2%, respectively. This poor clinical outcome was similar to other reports \[[@bib8],[@bib13]\]. Some studies further conducted a comparison of breast carcinosarcoma with other subtypes of breast metaplastic carcinoma. Hennessy et al. \[[@bib10]\] found that carcinosarcoma shared similar clinicopathological features with breast metaplastic carcinoma. Tseng et al. \[[@bib11]\]analyzed 1501 patients with breast metaplastic carcinoma from the SEER database, and they found that patients with carcinosarcoma had a worse disease-specific survival and overall survival compared with patients with metaplastic NOS. Our study showed that not only the whole carcinosarcoma group, but also the TNBC subgroup, uniformly showed a significantly worse clinical outcome than IDC. To the best of our knowledge, this is the first study comparing the prognosis of breast carcinosarcoma with IDC.

In the present study, we found that carcinosarcoma has distinct clinicopathological features. Compared with IDC, breast carcinosarcoma was correlated with higher grade, higher stage, larger tumor size, lower lymph node involvement, and a higher proportion of TNBC. In addition, carcinosarcoma showed a significantly worse clinical outcome than IDC. It appears that these aggressive clinicopathological features may be the cause of the poor outcome of carcinosarcoma. Then we used PSM to adjust for the uneven clinicopathological values, and a significant difference for the prognosis was still observed. To our knowledge, there have been no studies on breast carcinosarcoma that take advantage of PSM. Subgroup analysis for CS-TNBC and IDC-TNBC also showed similar results. All together, these results mean that a poor clinical outcome is characteristic of carcinosarcoma. However, few studies have focused on the molecular mechanism of breast carcinosarcoma. To improve the clinical outcome, further fundamental and clinical studies are required to explore the underlying molecular mechanism of breast carcinosarcoma.

Recently, Kennedy et al. \[[@bib14]\] analyzed 329 early/or locally advanced breast carcinosarcoma patients from 2004 to 2012 through the National Cancer Database. In that study, comorbidity index, insurance status, clinical T stage, surgical margin status, and treatment modality were associated with the greatest OS. In Mei et al.'s \[[@bib12]\] study of 25 operable breast carcinosarcomas, they showed that treatment modality was the only prognostic factor through multivariate COX regression. Through univariate COX regression analysis, we have also identified several potential prognostic factors for breast carcinosarcoma, such as stage, tumor size, distant metastasis, and grade. Due to the small sample size, we did not subject these factors for further multivariate analysis. With the expansion of the SEER database, more comprehensive and accurate information on prognostic factors for breast carcinosarcoma can be determined.

The present study had several limitations. First, some bias may occur due to the small sample size. For example, we observed that the unknown N stage (P = 0.003, HR = 73.170) and molecular subtype (P = 0.009, HR = 10.759) also correlated with poor OS. Second, the record pattern of the SEER database may potentially affect the analyses. For example, for some patients, the records were not clear on the use of chemotherapy and radiotherapy, but they may actually have received one of these treatments. This bias may underestimate the treatment effect. Therefore, a further expanded study is warranted to verify our findings.

In conclusion, we showed that breast carcinosarcoma has distinct clinicopathological features. Breast carcinosarcoma uniformly showed a significantly worse clinical outcome than IDC for both the whole group and the TNBC subgroup.
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